SML0527

Epalrestat

≥98% (HPLC)

• Synonym(e): (5Z)-5-[(2E)-2-Methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid
• Empirische Formel (Hill-System): C₁₅H₁₃NO₃S₂
• CAS-Nummer: 82159-09-9
• Molekulargewicht: 319.40
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: protect from light

Eigenschaften

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• storage condition: protect from light
• color: yellow to orange
• solubility: DMSO: 5 mg/mL, clear (warmed)
• storage temp.: −20°C
• SMILES string: S1\C(=C/C(=C/c2ccccc2)/C)\C(=O)N(C1=S)CC(=O)O
• InChI: 1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-
• InChI key: CHNUOJQWGUIOLD-NFZZJPOKSA-N

Beschreibung

Application

Epalrestat has been used as an aldose reductase inhibitor:

• in the dahomey larvae diet fed forDrosophila[1]
• for non-irradiated and X-ray irradiated human aldose reductase[2]
• to test its protective effect in mice with bleomycin-induced pulmonary fibrosis[3]

Biochem/physiol Actions

Epalrestat inhibits Aldose Reductase (AR) involved in the rate limiting step in the conversion of glucose to sorbitol under hyperglycemic conditions. Aldose reductase has been the target of multiple clinical investigatons to treat diabetic neuropathy and retinopathy. Epalrestat is an approved drug in Japan and India, used for the treatment of diabetic neuropathy.

Epalrestat is an Aldose Reductase inhibitor.

Features and Benefits

This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Other Notes

Light sensitve

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable